Two separate articles describing preclinical data of ACE-041 published

[News]

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 receptor, slows tumor growth and progression by inhibiting angiogenesis.

More... (http://www.news-medical.net/news/20100326/Two-separate-articles-describing-preclinical-data-of-ACE-041-published.aspx)